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Abstract. Documentation on the efficacy of artesunate in Africa is limited, and no experience of artesunate use in
Sudan is documented. Severe malaria in rural areas of Sudan, where facilities for the safe and effective use of parenteral
quinine are lacking, is a frequent problem. Early treatment with artesunate suppositories would provide a simple method
for use by unskilled staff and would be an alternative approach to treat malaria in settings with poor resources. We
describe a hospital-based study of rectal artesunate in 100 adult patients with severe falciparum malaria with a dose
derived from pharmacokinetic data (200 mg every 8 hours) over 3 days, which halted progression of severe disease and
had a low fatality rate. The dosage schedule led to a rapid clinical response and reduced parasite clearance and fever
subsidence times of (31.5 ± 10.1 hours) and (31.4 ± 11.1 hours). The sequential treatment of rectal artesunate with either
doxycycline or pyrimethamine/sulfadoxine or mefloquine resulted in similar clinical cure rates of around 100%, and the
combination of artesunate with either doxycycline or pyrimethamine/sulfadoxine was equally effective as mefloquine in
preventing recrudescence. There were no significant adverse effects or signs of toxicity related to the treatment observed
during the 28-day follow-up. The combination regimens could be used in areas where there is limited access to parenteral
therapy for malaria.
INTRODUCTION
The increase in malaria disease burden in Africa is of great
concern nationally and internationally. An estimated 300–500
million new cases of malaria and an estimated 1.5–2.7 million
deaths occur each year. The highest mortality (>90%) occurs
in children <5 years old in Africa.1 Plasmodium falciparum
malaria is associated with severe morbidity and mortality, and
in the absence of early diagnosis and effective treatment, it
may be fatal.2
Resistance to most antimalarial therapies is well docu-
mented worldwide. Multidrug resistance is an increasing
problem in Africa and poses a threat to the current manage-
ment of malaria with inexpensive drugs such as chloroquine
and pyrimethamine/sulfadoxine.3 Drugs derived from arte-
misinin have been shown to be extremely effective against
multidrug-resistant P. falciparum malaria and severe ma-
laria.4 Because their quantitative determination in biologic
fluid is a challenging problem, different dosage regimens have
been proposed that are largely empirical.5 The selection of
optimal dosage regimens requires precise information on the
drug’s pharmacokinetics.6
Artesunate is a semisynthetic derivative of artemisinin
whose water solubility facilitates absorption7 and provides an
advantage over artemisinin because it can be formulated as
oral, rectal, intramuscular, and intravenous preparations.
Artesunate is rapidly hydrolyzed to dihydroartemisinin,
which is the most active schizonticidal metabolite. Extravas-
cular administration of artesunate results in a more rapid sys-
temic availability of artesunate compared with intramuscular
artemether. This pharmacokinetic advantage may provide a
clinical advantage in the treatment of severe malaria.8 Rectal
artesunate has been shown to be absorbed rapidly, with a
considerable interindividual variability.9,10 Artesunate is
highly effective against multidrug-resistant falciparum ma-
laria and severe malaria in Vietnam, Thailand, China, and
Myanmar7; however, limited studies have been carried out in
Africa.
Suppositories of artesunate have been developed for rectal
administration as an alternative to oral or parenteral therapy.
Clinical studies of rectal administration of artesunate in the
treatment of malaria have been undertaken in Thailand, My-
anmar, Ecuador, Kenya, and Gabon.11–16 Table 1 summarizes
the doses used and the efficacy obtained in these studies.
Suppositories are a major advance in the treatment of severe
malaria, especially in rural settings, where resources are mea-
ger and the referral of cases is not possible. It is recommended
that further studies be carried out for the quantification of the
efficacy of artesunate suppositories in the treatment of severe
malaria.17,18
In Sudan, there has been a rapid spread of chloroquine-
resistant P. falciparum infections. Parenteral quinine is the
main drug widely used in the management of severe malaria.
It is available only in urban settings, where expertise and
equipment are available. The use of artesunate rectocaps
(Mepha Pharmaceutical Research, Aesch-Basel, Switzerland)
in treatment of severe malaria may provide advantages.
Although artemisinin compounds are effective against mul-
tidrug resistance, when administered alone, these agents have
led to recrudescence rates of 10–100%, depending on the
dose and duration of treatment and severity of the disease.19
Current recommendations are that artemisinin derivatives
should be used only in combination with other antimalarials
to reduce the development of resistant parasite strains. Me-
floquine has been used widely in combination with artemisi-
nin derivatives and has produced radical cure rates of
>90%.11,12 White and Olliaro20 and White et al.3 recom-
mended that clinical studies are needed to assess the efficacy
and safety of artemisinin compounds in combination with
other antimalarial drugs.
The objectives of this study were to investigate the efficacy
and safety of rectal artesunate in combination with 3 other
antimalarials in the treatment of severe malaria and to deter-
mine recrudescence rates after treatment of adult Sudanese
patients. The regimens evaluated were (1) artesunate sup-
positories for 3 days followed by doxycycline capsules for 4
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days, (2) artesunate suppositories for 3 days followed by
single-dose pyrimethamine/sulfadoxine tablets, and (3) arte-
sunate suppositories for 3 days followed by mefloquine tab-
lets divided into 2 equal doses 24 hours apart.
MATERIALS AND METHODS
Patients. The study was conducted at Omdurman Teaching
Hospital and the Tropical Disease Hospital in Khartoum
State. A total of 2,400 febrile patients were evaluated be-
tween January 2000 and January 2001. Patients with micro-
scopically diagnosed P. falciparum malaria were considered
for entry if they had clinical, biochemical, and parasitologic
evidence of severe malaria based on the World Health Orga-
nization (WHO) criteria of severe diseases.2,21
The inclusion criteria for a patient to enter the study were
evidence of severe malaria with 1 of the WHO criteria of
severe disease, age 18–60 years, and parasitemia of >10,000
parasites/l with P. falciparum alone. The exclusion criteria
included pregnancy, breast-feeding, hemorrhoids, previous
rectal surgery, diarrhea for 12 hours, and recent treatment
with an antimalarial over the previous 2 weeks. Patients who
fulfilled the inclusion criteria were selected randomly during
their presentation at the Accident and Emergency Depart-
ment and sequentially entered into 1 of 3 groups. The
Sudanese Ethical Committee (Federal Ministry of Health,
National Health Laboratory) gave ethical approval for the
study. A written consent was obtained from patients or rela-
tives, as was appropriate.
Clinical procedures.A full clinical examination was under-
taken by a general practitioner on admission. Comatose pa-
TABLE 1
Published results of clinical trials in the treatment of P. falciparum malaria by rectal artesunate
Country
No. of
patients Drug regimen
Type of
P. falciparum malaria
Radical cure
rate (%)
Recrudescence
rate (%)
Mortality
(%) Reference
Thailand 30 adults 200 mg at
0,4,8,12,24,36,
48,60 h
(1,600 mg) + MF
750 mg at 72 h,
500 mg at 84 h
Severe 92 8 0 Looareesuwan et al., 199511
Thailand 32 adults 200 mg at
0,4,8,12,36,48,
60 h (1,400 mg)
+ MF 750 mg at
72 h, 500 mg at
84 h
Severe 96 4 0 Looareesuwan et al., 199612
Thailand 31 adults 200 mg at
0,12,24,36,
48, 60 h
(1,200 mg) + MF
750 mg at 72 h,
500 mg at 84 h
Severe 89 11 0
Myanmar 13 adults 200 mg/12 h for
3 days, MF
750 mg on day 4
and 500 mg 12 h
apart
Severe 92.3 7.7 0 Thwe Ye et al., 199613
Myanmar 18 adults AS PR
200 mg/12 h on
day 1, 200 mg
on days 2 and
3, MF 750 mg
on day 4 and
500 mg 12 h
apart
Severe 77.8 22.2 0
Ecuador 40 adults 200 mg/8 h on
day 1,
200 mg/12 h on
days 2 and 3,
then MF
250 mg/8 h
started on day 4
Severe 97.5 2.5 2.5 Eduardo and Gomez, 199614
Kenya 22 adults 200 mg at
0,4,8,12,18,24,
48,60 h, then MF
TD 1,000 mg in
2 doses 8 h
apart
Severe 86.4 0 13.6 Bhatt et al., 199615
Gabon 12 children 50 mg at 0 and
4 h followed by
P/S SD at 20 h
Uncomplicated No 28 days follow-up,
no radical cure rate
– – Halpaap et al., 199816
Note. Radical cure rate (%): Clinical cure without recrudescence by day 28.
MF, mefloquine; P/S, Pyrimethamine/sulfadoxine; SD, single dose; TD, total dose.
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tients were graded using the Glasgow Coma Scale every 6
hours until the patient recovered full consciousness with a
Glasgow Coma Scale of 15. Rectal temperature, blood pres-
sure, pulse, and respiratory rate were measured every 6 hours
during the first 24 hours, then every 12 hours until day 4 and
once daily to day 7, then on the follow-up days 7, 14, 21, and
28. The patients were evaluated for the evolution of the signs
and symptoms, and any new events elicited during treatment
daily for 7 days and weekly till day 28 were recorded.
Laboratory procedures. The species differentiation was ob-
tained from thin smears. A parasite count was obtained using
thick blood films, counted as the number of parasites per 200
white blood cells. Parasite clearance was monitored using
thick blood films every 6 hours during the first 24 hours, then
every 12 hours to day 4 and daily to day 7. Follow-up films
were taken on days 14, 21, and 28. The thick blood films were
considered negative if no parasites were seen in 200 oil im-
mersion fields on thick smears.
Biochemical and hematologic tests included hemoglobin,
hematocrit, reticulocyte count, white blood cell total and dif-
ferential counts, plasma glucose, plasma total bilirubin, serum
urea, creatinine, and liver function tests. These tests were
done on admission and repeated on days 7, 14, 21, and 28.
More tests were performed as necessary for the management
of critically ill patients.
Management of patients. Patients with severe malaria re-
ceived nonspecific treatment according to the guidelines pub-
lished by Gilles2 and WHO.21 The specific treatment included
the use of the following antimalarial drugs: artesunate sup-
positories, 200 mg (Plasmotrim-200 Rectocaps-Mepha), me-
floquine tablets, 250 mg (Mephaquin-Mepha), doxycycline
capsules, 100 mg (Zadorin-Mepha), and pyrimethamine/
sulfadoxine, 25 mg/500 mg (Fansidar Roche).
Therapeutic regimens used.All patients were treated with
rectal artesunate, 200 mg every 8 hours for 3 days (total dose,
1,800 mg), then entered into an open-label design to receive
the combined drug as follows:
1. Group A (35 patients): Doxycycline capsules, 100 mg ev-
ery 12 hours for 4 days, started 12 hours after the last dose
of artesunate
2. Group B (35 patients): A single dose (3 tablets) of pyri-
methamine/sulfadoxine, 12 hours after the last dose of
artesunate
3. Group C (30 patients): Mefloquine tablets (total dose, 15
mg/kg body weight), split in 2 equal doses 24 hours apart,
started 12 hours after the last dose of artesunate
A pharmacokinetic study of oral and rectally administered
artesunate in Sudanese healthy volunteers was used to devise
the suggested dosage regimen of rectal artesunate, 200-mg
rectocaps every 8 hours.10 Patients were laid in a left lateral
position, and an artesunate rectocap was inserted into the
rectum beyond the anal verge by a trained nurse. The patients
were confined to bed for at least 1 hour after the insertion; if
the rectocap was expelled within 1 hour of administration,
another dose was inserted.
Evaluation criteria for the treatment efficacy and safety Effi-
cacy assessment. The following laboratory and clinical end
points were used to measure response to treatment objec-
tively: fever clearance time (time from the initiation of
therapy until body temperature decreased to 37°C and re-
mained so for at least 48 hours), time to consciousness (time
from the initiation of therapy until the Glasgow Coma Score
 15), clinical cure rate (the percentage of patients who had
initial recovery with complete initial disappearance of para-
sitemia within 7 days), and fatality rate (the percentage of
patients who died after the initiation of therapy). Laboratory
measures included parasite clearance time (time from the ini-
tiation of therapy until the first negative blood film that re-
mained negative for 48 hours), radical cure rate (the percent-
age of patients who had clinical cure without recrudescence
by day 28), and recrudescence rate (defined according to
WHO classification during 28-day follow-up). Improvement
of impaired biochemical and hematologic parameters (time
from the initiation of therapy until the improvement of the
impaired biochemical and hematologic parameters to normal
values) also was used.
Safety assessment. Side effects were defined as signs and
symptoms that first occurred or became more severe after
treatment was started. Any new events elicited during the
treatment also were considered as side effects. Biochemical
and hematologic parameters were evaluated before and after
initiation of therapy to detect any drug-associated effects.
Data analysis. The demographic, clinical, and laboratory
data for each patient were entered in a form, then entered in
SPSS V9 for the performance of the descriptive and compara-
tive statistical analysis. The comparison of data within the
groups was carried out by paired Student t-test for normally
distributed data and by Wilcoxon signed rank test for data
that were not normally distributed. One-way analysis of vari-
ance was used for the comparison between the groups.
RESULTS
A total of 2,400 adult patients who presented with fever or
a history of fever to the trial site were screened with blood
films during January 2000 to January 2001. Of patients, 420
(17.5%) were found to have positive blood films, 404 (96.2%)
had P. falciparum, and the rest had P. vivax. Of the 404 cases,
73.3% were considered to have uncomplicated P. falciparum
malaria, and 26.7% (n 108) had criteria ascribed by WHO
to severe malaria.
A total of 100 patients (79 men and 21 women) agreed to
participate in the study and received an initial treatment with
artesunate rectocaps for 3 days. For the second drug, the
patients were divided into 1 of the 3 treatment groups (35 in
group A, 35 in group B, and 30 in group C). Age range was
18–65 years with a mean (SD) of 30.5 (11.7) years, and weight
range was 42–97 kg with a mean (SD) of 64.9 (9.1) kg. The 3
groups were comparable in demographic data, clinical char-
acteristics, and laboratory findings (Table 2).
After the treatment regimens, surviving patients were fol-
lowed for 28 days. Home visits were conducted for patients
who failed to show for the follow-up. One patient died 7 hours
after the first dose of artesunate. Fourteen patients had cere-
bral malaria with a mean (SD) Glasgow Coma Scale of 6 (1);
49 patients were jaundiced with a plasma total bilirubin
greater than twice-normal laboratory range. All patients had
a parasitemia of >10,000 parasites/l, 19 patients had hyper-
pyrexia (>40.1°C), and 37 patients were hypoglycemic. Seven
patients had algid malaria with systolic blood pressure <80
mm Hg, and 12 patients had elevated serum creatinine and
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blood urea greater than twice normal. Of patients, 49 had >1
criteria of severe malaria as ascribed by WHO (Table 3).21
All patients clinically improved within 3 days of starting
treatment with artesunate rectocaps. Parasitemia clearance
and fever clearance times are shown in Figures 1 and 2. The
(mean ± SD) of initial parasitemia was 45,683 ± 42,068 para-
sites/l (range, 13,133–25,0000 parasites/l). In 87 patients,
parasitemia ranged from 13,133–100,000 parasites/l, and 13
patients had parasitaemia >100,000–250,000 parasites/l.
There was a highly statistically significant reduction in the
mean parasitemia at 6 hours and thereafter following artesu-
nate rectocaps administration (P < 0.001). The mean (SD)
decrease in parasitemia was 36.2% (2.5%) by 12 hours and
64.1% (29.6%) by 18 hours.
After the insertion of artesunate rectocaps, the overall
mean (SD) parasitemia clearance time was 31.5 hours (10.1
hours) (range, 18–72 hours). The mean (SD) reduction of
parasitemia by 24 hours was 88.8% (11.2%) and by 36 hours
was 99.8% (0.2%). At baseline enrollment, gametocytes were
detected in 5 patients. No new gametocytemia was detected
during the treatment or follow-up. The mean (SD) clearance
time of gametocytes was 4.2 (1.6) days, supporting the evi-
dence that artesunate clears gametocytes, preventing further
transmission.22
Figure 2 shows the clearance of fever. The overall mean
(SD) initial rectal temperature before treatment was 39°C
(1.3°C) (range, 34–40.6°C). There was a highly significant re-
duction from the initial elevated temperatures achieved by 6
hours after starting treatment (P < 0.001). The combined
mean (SD) fever clearance time was 31.4 (11.1) hours (range,
12–60 hours).
The mean resolution time for the signs and symptoms
ranged from 24–58.3 hours. All patients had excellent initial
clinical improvement, and 87% of the patients were asymp-
tomatic within 3 days of starting treatment. Full consciousness
was gained by 78.6% of comatose patients at 24 hours, and
the remaining patients regained normal higher function by 36
hours.
Hematologic parameters recovered with no evidence of
marrow suppression during artesunate treatment or after the
second drug in all treatment groups. Liver function, renal
function, and blood glucose were comparable at presentation
within the 3 treatment groups. All patients recovered except
for 1 death at 7 hours after the first artesunate dose. There
were no recrudescences in any patient by day 28 (radical cure
rates 100%).
FIGURE 1. Clearance of parasitemia.
TABLE 2
Mean ± SD of the clinical, hematologic, and biochemical parameters at admission of the 3 second-drug treatment groups
Parameter
Group A
(n  35)
Group B
(n  35)
Group C
(n  30)
Age (y) 28.2 ± 9.9 30.8 ± 11.9 33.0 ± 13.3
Weight (kg) 64.4 ± 7 66.7 ± 8.2 63.6 ± 11.9
Ratio of males/females 27/8 28/7 24/6
Glasgow Coma Scale 6 ± 2 7 ± 1 6 ± 1
Rectal temperature (°C) 38.8 ± 1.1 39.1 ± 1.2 39.1 ± 1.1
Blood pressure, systolic/diastolic 97 ± 12/53 ± 5 98 ± 15/56 ± 10 98 ± 12/54 ± 7
Parasitemia (parasites/l) 38,299 ± 31,300 39,753 ± 30,615 61,214 ± 58,620
Hemoglobin (g/dl) (men, 13–17 g/dl; women, 12–15 g/dl) 12.4 ± 2.2 13.8 ± 1.6 12.5 ± 2.1
Plasma total bilirubin (mg/dl) (1 mg/dl) 2.2 ± 1.6 2.6 ± 1.7 3.3 ± 3.1
Serum creatinine (mg/dl) (0.5–1.5 mg/dl) 1.5 ± 0.8 1.6 ± 0.7 1.6 ± 0.8
Plasma glucose (mg/dl) (55–110 mg/dl) 52.7 ± 7.5 53.3 ± 8.9 53.5 ± 8.5
Note. Values in parentheses are laboratory normal range.
TABLE 3
Patients with more than one criteria of severe malaria
Criteria
No.
patients
Cerebral malaria (GCS  6) + hyperpyrexia
(>40.1°C) + generalized convulsions
7
Cerebral malaria (GCS > 6  8) + plasma total biliru-
bin >3 mg/dl
5
Cerebral malaria (GCS  6) + hyperpyrexia
(>40.1°C) + plasma total bilirubin >3 mg/dl
+ serum creatinine >3 mg/dl
2
Hyperparasitemia (>100.000 P/l) + plasma total bili-
rubin >6 mg/dl + hyperpyrexia (>40.1°C) + general-
ized convulsions + hemoglobin <8.5 g/dl
9
Hyperparasitemia (>100.000 P/l) + plasma total bili-
rubin >3 mg/dl + hypoglycemia <40 mg/dl + gener-
alized convulsions + serum creatinine >3 mg/dl
4*
Algid malaria (SBP < 80 mmHg) + plasma total bili-
rubin >3 mg/dl
5
Algid malaria (SBP < 80 mmHg) + plasma total bili-
rubin >3 mg/dl + serum creatinine >3 mg/dl
2
Hyperpyrexia (>40.1°C) + generalized convulsions +
plasma total bilirubin >3 mg/dl
1
Serum creatinine >3 mg/dl + urine output <400 ml /24
h + hypoglycemia <40 mg/dl + plasma total biliru-
bin >3 mg/dl
4
Hypoglycemia <40 mg/dl + generalized convulsions +
plasma total bilirubin >3 mg/dl
10
* One fatal outcome.
The criteria of severe falciparum malaria as ascribed by WHO, 2000.
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DISCUSSION
The present study investigated a larger number of patients
than reported in other studies. Using pharmacokinetic data
from healthy volunteers, an appropriate dose of artesunate
was selected for administration per rectum that would be ex-
pected to provide blood levels of dihydroartemesinin above
the minimum inhibitory concentration that eliminates 90% of
the parasites (MIC90) for 5.3 ± 2.1 hours.
10 The rapid parasite
clearance and deffervescence of fever in all 99 patients con-
firms the dosing schedule in this group of patients was entirely
appropriate. The parasitemia and fever clearance times in this
study were significantly shorter than that reported by Looa-
reesuwan et al.11,12 and Thwe et al.13 but not significantly
different from that reported by Eduardo and Gomez14 and
Bhatt et al.15
The choice of second agent was made based on available
data of mefloquine from Southeast Asia and cost because
pyrimethamine/sulfadoxine and doxycycline are inexpensive
and widely available. All 3 drugs proved equally effective,
producing radical cure rates of 100%. The only death in the
study was a 50-year-old man, who despite a reduction in par-
asitemia at 6 hours from 160,000 to 142,000 parasites/l died
suddenly 7 hours after starting treatment. Previous studies
reported fatality rates of 40% in severely ill malaria pa-
tients.23 The mortality rates reported in 2 other studies using
artesunate rectocaps for the treatment of severe malaria were
2.5% and 13.6%.14,15 In these 2 studies, the number of pa-
tients and the total dose of rectal artesunate were less than in
our study (Table 1). We accept that not all subjects meet
similar criteria to those published studies, but this study was
not intended to show a reduction in mortality as an outcome
measure, but this was noted, and we comment on it as a
positive finding.
The selection criteria used the WHO21 definition of severe
malaria to include hyperparasitemia, jaundice, hyperpyrexia,
cerebral involvement, renal impairment, and prostration, and
these were used for selecting patients for the study. Because
many of these criteria are clinical and subjective, comparison
of disease severity with other studies is difficult. About one
quarter of all 404 cases diagnosed as P. falciparum (26.7%)
were considered severe, however, and recruited into the
study. It is of note that only 1 death occurred, and recovery
occurred in more than three quarters with 3 days of artesu-
nate treatment. Because the formulation was a rectal supposi-
tory, cultural objection to the use of suppositories needed to
be considered. Cultural acceptance is variable and responds
to education. There was little resistance to the use of the
suppositories by patients or their relatives.
The clinical and laboratory findings during and after the
treatment showed no evidence of toxicity or side effects to the
3 combination regimens during treatment and the 28-day fol-
low-up. In group B, there was an increase in the number of
patients with hemoglobin and hematocrit below normal at
days 7 and 14, which suggested that this combination may
have an adverse effect. Previous studies using pyrimethamine/
sulfadoxine combined with artesunate in the treatment of un-
complicated falciparum malaria reported that there were no
adverse effects on laboratory parameters.24 The clinical sig-
nificance of this finding remains to be confirmed in a larger
number of patients.
In studies in which artemisinin compounds were adminis-
tered alone, recrudescence rates varied from 10% to 100%
depending on the dose, duration of treatment, and severity of
the disease.19 These drugs often are combined with meflo-
quine to reduce the rate of recrudescence. Limited studies
reported the efficacy of doxycycline or pyrimethamine/
sulfadoxine combined with artesunate in treatment of uncom-
plicated malaria. The present results indicate that sequential
treatment of severe malaria with artesunate rectocaps fol-
lowed by either doxycycline (100 mg every 12 hours for 4
days) or a single dose of pyrimethamine/sulfadoxine was
equally effective to that followed by mefloquine in preventing
recrudescence. The dosage regimen of mefloquine (total dose
15 mg/kg body weight) divided in 2 equal doses 24 hours apart
used in this study improved its tolerability because no serious
adverse effects occurred.
Artesunate rectocaps in treatment of severe malaria have
many advantages in rural settings in developing countries
such as Sudan. Their administration does not require sophis-
ticated facilities and skilled personnel, and they can be used as
an alternative to parenteral quinine with all its known side
effects. The use of artesunate rectocaps in rural areas where
malaria transmission is higher and the disease is more preva-
lent is more appropriate for the type of health facilities avail-
able. The early administration of treatment to patients where
referral is not possible, especially for children, could reduce
complications and reduce mortality. The use of a single dose
of pyrimethamine/sulfadoxine or 2 doses of mefloquine in
adults and children would improve compliance to the impor-
tant second drug necessary to prevent resistance. Doxycycline
can be used as an alternative in adults.
The main goal of this study was to evaluate the efficacy and
safety of an alternative therapy to parenteral quinine in areas
where there is poor access to well-structured health facilities,
such as exist in Sudan and many other parts of the Third
World and where patient referral is impractical. A novel dos-
age regimen of artesunate rectocaps (200 mg every 8 hours for
3 days) achieved substantial and rapid decreases in parasit-
emia and fever in patients presenting with severe falciparum
malaria. The drug regimen was well tolerated and produced a
clinical cure in most patients by day 3. The addition of 1 of 3
second-line drugs prevented recrudescence of malaria. The
regimen was designed for use in settings with poor resources
and limited expertise, and its ease of use may have a signifi-
cant impact and effectiveness that may reduce complications
and mortality from falciparum malaria. The sequential com-
FIGURE 2. Clearance of fever.
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binations of artesunate rectocaps followed by doxycycline or
pyrimethamine/sulfadoxine were equally effective as meflo-
quine in preventing recrudescence and in this study had a
100% radical cure rate. The combination regimens seem safe
and highly effective and could be lifesaving in patients with
severe malaria, particularly in rural areas. The present results
can be pooled in the future with results from other areas to
determine the actual efficacy of artesunate suppositories com-
pared with current therapeutic options used in different re-
gions of the world.
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